ReviewBMJ open2023
Navigating data governance associated with real-world data for public benefit: an overview in the UK and future considerations.
Review in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review.Advances in therapy · 2024Pooled it
- Challenges and possibilities of public and patient involvement for early-career researchers: pedagogy, practice and data governance.Research involvement and engagement · 2026Article
- Anonymization and visualization of health data and biomarkers.NPJ digital medicine · 2026Article
- Unlocking insights: general practice staff perspectives on sharing general practice data for research - a scoping review.BMC primary care · 2025Article
- Medical Imaging Data Calls for a Thoughtful and Collaborative Approach to Data Governance.PLOS digital health · 2025Article
- Article
- Enhancing Ophthalmic Diagnosis and Treatment with Artificial Intelligence.Medicina (Kaunas, Lithuania) · 2025Review
- Navigating barriers to real-world evidence utilization for drug regulatory affairs and market access in Saudi Arabia.Frontiers in pharmacology · 2025Article
- UpSMART: five years of digital innovation in cancer clinical research-achievements, challenges, and recommendations.Frontiers in digital health · 2025Article
- Generalisable Overview of Study Risk for Lead Investigators Needing Guidance (GOSLING): A data governance risk tool.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Real-world data encompass data primarily captured for the provision or operation of services, for example, electronic health records for direct care purposes, but which may have secondary uses for informing research or commissioning. Public benefit is potentially forfeited by the underutilisation of real-world data for secondary uses, in part due to risk aversion when faced with the prospect of navigating necessary and important data governance processes. Such processes can be perceived as complex, daunting, time-consuming and exposing organisations to risk. By providing an overview description and discussion around the role of six key legal and information governance frameworks and their role regarding responsible data access, linkage and sharing, our intention is to make data governance a less daunting prospect and reduce the perception that it is a barrier to secondary uses, thus enabling public benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.